Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giuseppe Matullo is active.

Publication


Featured researches published by Giuseppe Matullo.


Nature Genetics | 2009

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Thorunn Rafnar; Patrick Sulem; Simon N. Stacey; Frank Geller; Julius Gudmundsson; Asgeir Sigurdsson; Margret Jakobsdottir; Hafdis T. Helgadottir; Steinunn Thorlacius; Katja K. Aben; Thorarinn Blondal; Thorgeir E. Thorgeirsson; Gudmar Thorleifsson; Kristleifur Kristjansson; Kristin Thorisdottir; Rafn Ragnarsson; Bardur Sigurgeirsson; Halla Skuladottir; Tomas Gudbjartsson; Helgi J. Ísaksson; Gudmundur V. Einarsson; Kristrun R. Benediktsdottir; Bjarni A. Agnarsson; Karl Olafsson; Anna Salvarsdottir; Hjordis Bjarnason; Margret Asgeirsdottir; Kari T. Kristinsson; Sigurborg Matthiasdottir; Steinunn G Sveinsdottir

The common sequence variants that have recently been associated with cancer risk are particular to a single cancer type or at most two. Following up on our genome-wide scan of basal cell carcinoma, we found that rs401681[C] on chromosome 5p15.33 satisfied our threshold for genome-wide significance (OR = 1.25, P = 3.7 × 10−12). We tested rs401681 for association with 16 additional cancer types in over 30,000 cancer cases and 45,000 controls and found association with lung cancer (OR = 1.15, P = 7.2 × 10−8) and urinary bladder, prostate and cervix cancer (ORs = 1.07−1.31, all P < 4 × 10−4). However, rs401681[C] seems to confer protection against cutaneous melanoma (OR = 0.88, P = 8.0 × 10−4). Notably, most of these cancer types have a strong environmental component to their risk. Investigation of the region led us to rs2736098[A], which showed stronger association with some cancer types. However, neither variant could fully account for the association of the other. rs2736098 corresponds to A305A in the telomerase reverse transcriptase (TERT) protein and rs401681 is in an intron of the CLPTM1L gene.


Nature Genetics | 2008

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer

Lambertus A. Kiemeney; Steinunn Thorlacius; Patrick Sulem; Frank Geller; Katja K. Aben; Simon N. Stacey; Julius Gudmundsson; Margret Jakobsdottir; Jon Thor Bergthorsson; Asgeir Sigurdsson; Thorarinn Blondal; J. Alfred Witjes; Sita H. Vermeulen; Christina A. Hulsbergen-van de Kaa; Dorine W. Swinkels; Martine Ploeg; Erik B. Cornel; H. Vergunst; Thorgeir E. Thorgeirsson; Daniel F. Gudbjartsson; Sigurjon A. Gudjonsson; Gudmar Thorleifsson; Kari T. Kristinsson; Magali Mouy; Steinunn Snorradottir; Donatella Placidi; Marcello Campagna; Cecilia Arici; Kvetoslava Koppova; Eugene Gurzau

We conducted a genome-wide SNP association study on 1,803 urinary bladder cancer (UBC) cases and 34,336 controls from Iceland and The Netherlands and follow up studies in seven additional case-control groups (2,165 cases and 3,800 controls). The strongest association was observed with allele T of rs9642880 on chromosome 8q24, 30 kb upstream of MYC (allele-specific odds ratio (OR) = 1.22; P = 9.34 × 10−12). Approximately 20% of individuals of European ancestry are homozygous for rs9642880[T], and their estimated risk of developing UBC is 1.49 times that of noncarriers. No association was observed between UBC and the four 8q24 variants previously associated with prostate, colorectal and breast cancers, nor did rs9642880 associate with any of these three cancers. A weaker signal, but nonetheless of genome-wide significance, was captured by rs710521[A] located near TP63 on chromosome 3q28 (allele-specific OR = 1.19; P = 1. 15 × 10−7).


International Journal of Cancer | 2001

DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study

Giuseppe Matullo; Simonetta Guarrera; Sonia Carturan; Marco Peluso; C. Malaveille; Laura Davico; Alberto Piazza; Paolo Vineis

Individuals differ widely in their ability to repair DNA damage, and DNA‐repair deficiency may be involved in modulating cancer risk. In a case‐control study of 124 bladder‐cancer patients and 85 hospital controls (urological and non‐urological), 3 DNA polymorphisms localized in 3 genes of different repair pathways (XRCC1‐Arg399Gln, exon 10; XRCC3‐Thr241Met, exon 7; XPD‐Lys751Gln, exon 23) have been analyzed. Results were correlated with DNA damage measured as 32P‐post‐labeling bulky DNA adducts in white blood cells from peripheral blood. Genotyping was performed by PCR‐RFLP analysis, and allele frequencies in cases/controls were as follows: XRCC1‐399Gln = 0.34/0.39, XRCC3‐241Met = 0.48/0.35 and XPD‐751Gln = 0.42/0.42. Odds ratios (ORs) were significantly greater than 1 only for the XRCC3 (exon 7) variant, and they were consistent across the 2 control groups. XPD and XRCC1 appear to have no impact on the risk of bladder cancer. Indeed, the effect of XRCC3 was more evident in non‐smokers [OR = 4.8, 95% confidence interval (CI) 1.1–21.2]. XRCC3 apparently interacted with the N‐acetyltransferase type 2 (NAT‐2) genotype. The effect of XRCC3 was limited to the NAT‐2 slow genotype (OR = 3.4, 95% CI 1.5–7.9), suggesting that XRCC3 might be involved in a common repair pathway of bulky DNA adducts. In addition, the risk of having DNA adduct levels above the median was higher in NAT‐2 slow acetylators, homozygotes for the XRCC3‐241Met variant allele (OR = 14.6, 95% CI 1.5–138). However, any discussion of interactions should be considered preliminary because of the small numbers involved. Our results suggest that bladder‐cancer risk can be genetically modulated by XRCC3, which may repair DNA cross‐link lesions produced by aromatic amines and other environmental chemicals.


BMJ | 2005

Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study

Paolo Vineis; Luisa Airoldi; Fabrizio Veglia; L Olgiati; R Pastorelli; Herman Autrup; Alison M. Dunning; Seymour Garte; Emmanuelle Gormally; Pierre Hainaut; C. Malaveille; Giuseppe Matullo; Marco Peluso; Kim Overvad; Anne Tjønneland; F. Clavel-Chapelon; Heiner Boeing; Krogh; D. Palli; Salvatore Panico; R. Tumino; Bas Bueno-de-Mesquita; P.H.M. Peeters; G. Berglund; Göran Hallmans; Rodolfo Saracci; Elio Riboli

Abstract Objectives To investigate the association between environmental tobacco smoke, plasma cotinine concentration, and respiratory cancer or death. Design Nested case-control study within the European prospective investigation into cancer and nutrition (EPIC). Participants 303 020 people from the EPIC cohort (total 500 000) who had never smoked or who had stopped smoking for at least 10 years, 123 479 of whom provided information on exposure to environmental tobacco smoke. Cases were people who developed respiratory cancers or died from respiratory conditions. Controls were matched for sex, age (plus or minus 5 years), smoking status, country of recruitment, and time elapsed since recruitment. Main outcome measures Newly diagnosed cancer of lung, pharynx, and larynx; deaths from chronic obstructive pulmonary disease or emphysema. Plasma cotinine concentration was measured in 1574 people. Results Over seven years of follow up, 97 people had newly diagnosed lung cancer, 20 had upper respiratory cancers (pharynx, larynx), and 14 died from chronic obstructive pulmonary disease or emphysema. In the whole cohort exposure to environmental tobacco smoke was associated with increased risks (hazard ratio 1.30, 95% confidence interval 0.87 to 1.95, for all respiratory diseases; 1.34, 0.85 to 2.13, for lung cancer alone). Higher results were found in the nested case-control study (odds ratio 1.70, 1.02 to 2.82, for respiratory diseases; 1.76, 0.96 to 3.23, for lung cancer alone). Odds ratios were consistently higher in former smokers than in those who had never smoked; the association was limited to exposure related to work. Cotinine concentration was clearly associated with self reported exposure (3.30, 2.07 to 5.23, for detectable/non-detectable cotinine), but it was not associated with the risk of respiratory diseases or lung cancer. Frequent exposure to environmental tobacco smoke during childhood was associated with lung cancer in adulthood (hazard ratio 3.63, 1.19 to 11.11, for daily exposure for many hours). Conclusions This large prospective study, in which the smoking status was supported by cotinine measurements, confirms that environmental tobacco smoke is a risk factor for lung cancer and other respiratory diseases, particularly in ex-smokers.


Nature Genetics | 2009

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

Xifeng Wu; Yuanqing Ye; Lambertus A. Kiemeney; Patrick Sulem; Thorunn Rafnar; Giuseppe Matullo; Daniela Seminara; Teruhiko Yoshida; Norihisa Saeki; Angeline S. Andrew; Colin P. Dinney; Bogdan Czerniak; Zuo-Feng Zhang; Anne E. Kiltie; D. Timothy Bishop; Paolo Vineis; Stefano Porru; Frank Buntinx; Eliane Kellen; Maurice P. Zeegers; Rajiv Kumar; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Jose I. Mayordomo; Manuel Sanchez; Berta Saez; Annika Lindblom; Petra J. de Verdier; Gunnar Steineck

We conducted a genome-wide association study on 969 bladder cancer cases and 957 controls from Texas. For fast-track validation, we evaluated 60 SNPs in three additional US populations and validated the top SNP in nine European populations. A missense variant (rs2294008) in the PSCA gene showed consistent association with bladder cancer in US and European populations. Combining all subjects (6,667 cases, 39,590 controls), the overall P-value was 2.14 × 10−10 and the allelic odds ratio was 1.15 (95% confidence interval 1.10–1.20). rs2294008 alters the start codon and is predicted to cause truncation of nine amino acids from the N-terminal signal sequence of the primary PSCA translation product. In vitro reporter gene assay showed that the variant allele significantly reduced promoter activity. Resequencing of the PSCA genomic region showed that rs2294008 is the only common missense SNP in PSCA. Our data identify rs2294008 as a new bladder cancer susceptibility locus.


Circulation | 1998

Plasma Activity and Insertion/Deletion Polymorphism of Angiotensin I–Converting Enzyme A Major Risk Factor and a Marker of Risk for Coronary Stent Restenosis

Flavio Ribichini; Giuseppe Steffenino; Antonio Dellavalle; Giuseppe Matullo; Elena Colajanni; Terenzio Camilla; Antonello Vado; Gabriella Benetton; Eugenio Uslenghi; Alberto Piazza

BACKGROUND Tissue proliferation is almost invariably observed in recurrent lesions within stents, and ACE, a factor of smooth muscle cell proliferation, may play an important role. Plasma ACE level is largely controlled by the insertion/deletion (I/D) polymorphism of the enzyme gene. The association among restenosis within coronary stents, plasma ACE level, and the I/D polymorphism is analyzed in the present prospective study. METHODS AND RESULTS One hundred seventy-six consecutive patients with successful, high-pressure, elective stenting of de novo lesions in the native coronary vessels were considered. At follow-up angiography, recurrence was observed in 35 patients (19.9%). Baseline clinical and demographic variables, plasma glucose and serum fibrinogen levels, lipid profile, descriptive and quantitative angiographic data, and procedural variables were not significantly different in patients with and without restenosis; mean plasma ACE levels (+/-SEM) were 40.8+/-3.5 and 20.7+/-1.0 U/L, respectively (P<.0001). Diameter stenosis percentage and minimum luminal diameter at 6 months showed statistically significant correlation with plasma ACE level (r=.352 and -.387, respectively P<.001). Twenty-one of 62 patients (33.9%) with D/D genotype, 13 of 80 (16.3%) with I/D genotype, and 1 of 34 (2.9%) with I/I genotype showed recurrence; the restenosis rate for each genotype is consistent with a codominant expression of the allele D. CONCLUSIONS In a selected cohort of patients, both the D/D genotype of the ACE gene, and high plasma activity of the enzyme are significantly associated with in-stent restenosis. Continued study with clinically different subsets of patients and various stent designs is warranted.


International Journal of Cancer | 2001

DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample.

Domenico Palli; Antonio Russo; Giovanna Masala; Calogero Saieva; Simonetta Guarrera; Sonia Carturan; Armelle Munnia; Giuseppe Matullo; Marco Peluso

Peripheral blood DNA adducts have been considered an acceptable surrogate for target tissues and possibly predictive of cancer risk. A group of 114 workers exposed to traffic pollution and a random sample of 100 residents were drawn from the EPIC cohort in Florence, a population recently shown to present increased DNA adduct levels (Palli et al., Int J Cancer 2000;87:444–51). DNA bulky adducts and 3 DNA repair gene polymorphisms were analyzed in peripheral leukocytes donated at enrollment, by using 32P‐postlabeling and PCR methods, respectively. Adduct levels were significantly higher for traffic workers among never smokers (p = 0.03) and light current smokers (p = 0.003). In both groups, urban residents tended to show higher levels than those living in suburban areas, and a seasonal trend emerged with adduct levels being highest in summer and lowest in winter. Traffic workers with at least 1 variant allele for XPD‐Lys751Gln polymorphism had significantly higher levels in comparison to workers with 2 common alleles (p = 0.02). A multivariate analysis (after adjustment for age, season, area of residence, smoking, XPD‐Lys751Gln genotype and antioxidant intake) showed a significant 2‐fold association between occupational exposure and higher levels of adducts (odds ratio 2.1; 95% confidence interval 1.1–4.2), in agreement with recent pooled estimates of increased lung cancer risk for similar job titles. Our results suggest that traffic workers and the general population in Florence are exposed to high levels of genotoxic agents related to vehicle emissions. Photochemical pollution in warmer months might be responsible for the seasonal trend of genotoxic damage in this Mediterranean urbanized area.


Mutagenesis | 2011

STrengthening the reporting of OBservational studies in Epidemiology—Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement

Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B. Farmer; John P. A. Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H. Phillips; Bernadette Schoket; Ulf Strömberg; Roel Vermeulen; Christopher P. Wild; Miquel Porta; Paolo Vineis

Advances in laboratory techniques have led to a rapidly increasing use of biomarkers in epidemiological studies. Biomarkers of internal dose, early biological change, susceptibility and clinical outcomes are used as proxies for investigating interactions between external and / or endogenous agents and body components or processes. The need for improved reporting of scientific research led to influential statements of recommendations such as the STrengthening Reporting of OBservational studies in Epidemiology (STROBE) statement. The STROBE initiative established in 2004 aimed to provide guidance on how to report observational research. Its guidelines provide a user-friendly checklist of 22 items to be reported in epidemiological studies, with items specific to the three main study designs: cohort studies, case-control studies and cross-sectional studies. The present STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME) initiative builds on the STROBE statement implementing nine existing items of STROBE and providing 17 additional items to the 22 items of STROBE checklist. The additions relate to the use of biomarkers in epidemiological studies, concerning collection, handling and storage of biological samples; laboratory methods, validity and reliability of biomarkers; specificities of study design; and ethical considerations. The STROBE-ME recommendations are intended to complement the STROBE recommendations.


Nature Genetics | 2010

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer

Lambertus A. Kiemeney; Patrick Sulem; Søren Besenbacher; Sita H. Vermeulen; Asgeir Sigurdsson; Gudmar Thorleifsson; Daniel F. Gudbjartsson; Simon N. Stacey; Julius Gudmundsson; Carlo Zanon; Jelena Kostic; Gisli Masson; Hjordis Bjarnason; Stefan Palsson; Oskar B Skarphedinsson; Sigurjon A. Gudjonsson; J. Alfred Witjes; Anne J. Grotenhuis; Gerald W. Verhaegh; D. Timothy Bishop; Sei C. Sak; Ananya Choudhury; Faye Elliott; Jennifer H. Barrett; Carolyn D. Hurst; Petra J. de Verdier; Charlotta Ryk; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova

Previously, we reported germline DNA variants associated with risk of urinary bladder cancer (UBC) in Dutch and Icelandic subjects. Here we expanded the Icelandic sample set and tested the top 20 markers from the combined analysis in several European case-control sample sets, with a total of 4,739 cases and 45,549 controls. The T allele of rs798766 on 4p16.3 was found to associate with UBC (odds ratio = 1.24, P = 9.9 × 10−12). rs798766 is located in an intron of TACC3, 70 kb from FGFR3, which often harbors activating somatic mutations in low-grade, noninvasive UBC. Notably, rs798766[T] shows stronger association with low-grade and low-stage UBC than with more aggressive forms of the disease and is associated with higher risk of recurrence in low-grade stage Ta tumors. The frequency of rs798766[T] is higher in Ta tumors that carry an activating mutation in FGFR3 than in Ta tumors with wild-type FGFR3. Our results show a link between germline variants, somatic mutations of FGFR3 and risk of UBC.


International Journal of Cancer | 2006

Air pollution and risk of lung cancer in a prospective study in Europe

Paolo Vineis; Gerard Hoek; Michal Krzyzanowski; Federica Vigna-Taglianti; Fabrizio Veglia; Luisa Airoldi; Herman Autrup; Alison M. Dunning; Seymour Garte; Pierre Hainaut; C. Malaveille; Giuseppe Matullo; Kim Overvad; Ole Raaschou-Nielsen; Françoise Clavel-Chapelon; J. Linseisen; Heiner Boeing; Antonia Trichopoulou; Domenico Palli; Marco Peluso; Vittorio Krogh; Rosario Tumino; Salvatore Panico; H. Bas Bueno-de-Mesquita; Petra H.M. Peeters; Eiliv Lund; Carlos A. González; Carmen Martinez; Miren Dorronsoro; Aurelio Barricarte

To estimate the relationship between air pollution and lung cancer, a nested case‐control study was set up within EPIC (European Prospective Investigation on Cancer and Nutrition). Cases had newly diagnosed lung cancer, accrued after a median follow‐up of 7 years among the EPIC exsmokers (since at least 10 years) and never smokers. Three controls per case were matched. Matching criteria were gender, age (±5 years), smoking status, country of recruitment and time elapsed between recruitment and diagnosis. We studied residence in proximity of heavy traffic roads as an indicator of exposure to air pollution. In addition, exposure to air pollutants (NO2, PM10, SO2) was assessed using concentration data from monitoring stations in routine air quality monitoring networks. Cotinine was measured in plasma. We found a nonsignificant association between lung cancer and residence nearby heavy traffic roads (odds ratio = 1.46, 95% confidence interval, CI, 0.89–2.40). Exposure data for single pollutants were available for 197 cases and 556 matched controls. For NO2 we found an odds ratio of 1.14 (95% CI, 0.78–1.67) for each increment of 10 μg/m3, and an odds ratio of 1.30 (1.02–1.66) for concentrations greater than 30 μg/m3. The association with NO2 did not change after adjustment by cotinine and additional potential confounders, including occupational exposures. No clear association was found with other pollutants.

Collaboration


Dive into the Giuseppe Matullo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paolo Vineis

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salvatore Panico

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rosario Tumino

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge